Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Rapid, sustained and reversible pharmacodynamics of DAC HYP in MS patients supports mechanism of action via modulation of the IL-2 pathway
Perk Ablation Ameliorates Myelination in S63del-Charcot-Marie-Tooth 1B Neuropathy.
Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study.
Association between the three functional miR-146a single-nucleotide polymorphisms, rs2910164, rs57095329, and rs2431697, and autoimmune disease susceptibility: A meta-analysis.
Long-term Impact of Early MS Treatment with Interferon Beta-1b (IFNB-1b): Clinical, MRI, Employment, and Patient-Reported Outcomes (PROs) at the 11-Year Follow-up of BENEFIT (BENEFIT 11)
Rebound Relapses After Ceasing Another Disease-Modifying Treatment in Patients With Multiple Sclerosis: Are There Lessons to Be Learned?
Defining the Role of Physiotherapy in Palliative Care in Multiple Sclerosis.
Techniques and technologies for the bioanalysis of Sativex(®), metabolites and related compounds.
The role of stem cell therapy in multiple sclerosis: An overview of the current status of the clinical studies.
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.
PiB and other amyloid-PET tracers for the study of white matter and multiple sclerosis.
Imaging in Pediatric Demyelinating and Inflammatory Diseases of Brain- Part 2.
Akt Regulates Axon Wrapping and Myelin Sheath Thickness in the PNS.
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients.
Three-Month Test-Retest Reliability of Center of Pressure Motion During Standing Balance in Individuals with Multiple Sclerosis.
Reassessing the risk of natalizumab-associated PML.
The endocannabinoid system and multiple sclerosis.
Mitoxantrone induces natural killer cell maturation in patients with secondary progressive multiple sclerosis.
Genzyme’s once-daily, oral AUBAGIO® (teriflunomide) approved in Argentina for the treatment of relapsing multiple sclerosis
Mutually enhancing anti-inflammatory activities of dimethyl fumarate and NF-κB inhibitors - Implications for dose-sparing combination therapies.
Ncx3 gene ablation impairs oligodendrocyte precursor response and increases susceptibility to experimental autoimmune encephalomyelitis.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Thrombotic microangiopathy due to acquired ADAMTS13 deficiency in a patient receiving interferon-beta treatment for multiple sclerosis.
Novartis announces Russian regulatory approval for Gilenya®, a once-daily oral multiple sclerosis therapy and first in a new class
BRIEF: Teva files for Copaxone-Laquinimod patent

Pages